Upfront Briefing
Two-track tape: argenx delivered a clean Phase 3 ADAPT OCULUS topline for VYVGART in ocular myasthenia gravis, reinforcing the “FcRn franchise durability” story as the lifecycle engine keeps compounding.
Meanwhile, deal + financing flow stayed busy: Asahi Kasei agreed to acquire Aicuris for $920M (a reminder strategics still pay up for late-stage, de-risked assets), and Larimar priced an upsized $100M underwritten offering — runway secured, dilution digested.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,946.1 |
+0.8% |
+1.5% |
| Nasdaq 100 |
25,329.0 |
+1.4% |
+0.3% |
| Russell 2000 |
2,663.3 |
+0.4% |
+7.3% |
| Healthcare (XLV) |
157.8 |
(0.0%) |
+2.0% |
| Biotech (XBI) |
128.3 |
(0.7%) |
+5.2% |
| Nasdaq Biotech (NBI) |
6,030.4 |
(0.5%) |
+5.7% |
| Clinical Trials (BBC) |
42.8 |
+0.3% |
+10.6% |
|
-
Mega-cap tech/AI momentum pushed the Nasdaq-led rally (Nasdaq 100 +1.4%) into the close, while defensives lagged (XLV ~flat).
-
Biotech underperformed despite “risk-on” tape: dilution overhang (follow-ons) and single-name catalysts kept beta choppy (XBI/NBI red on the day).
The Big 3
|
1
|
argenx posts positive Phase 3 ADAPT OCULUS topline for VYVGART
|
- argenx reported positive topline results from the Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis. The data could support lifecycle growth beyond current uses.
-
Why it matters:
Ocular MG is a meaningful label-expansion wedge: it broadens FcRn use into an earlier/less-severe phenotype, supports longer-duration VYVGART growth, and strengthens the “franchise durability” narrative as competition intensifies across IgG-mediated diseases.
- Source: PR
|
|
2
|
Asahi Kasei to buy German biotech Aicuris for $920M
|
- Asahi Kasei plans to acquire German biotech Aicuris for $920M. The takeout highlights strategic appetite for private biotech assets.
-
Why it matters:
€780M all-cash for Aicuris is a clean “pay up for late-stage + near-commercial infectives” signal: you’re buying (i) PREVYMIS-linked economics plus (ii) a wholly owned Phase 3 asset (pritelivir) and (iii) a Phase 2-ready follow-on (AIC468). For investors, it reinforces that credible, late-stage European private biotechs can still clear premium exits without U.S. public comps cooperating.
-
Source:
Endpoints
|
| 3 | Larimar prices upsized $100M underwritten public offering |
-
Larimar Therapeutics priced an upsized $100 million underwritten public offering. The financing could extend runway while increasing near-term share supply.
-
Why it matters:
Underwritten follow-ons are “runway now, re-rate later”: Larimar’s upsized $100M raise (20M shares at $5.00, plus a 3M share greenshoe) extends operating runway, but mechanically lifts share count/float — often pressuring the stock near term as buyside models re-underwrite dilution and financing cadence.
-
Source:
PR
|
Everything Else that broke
- argenx reports full-year 2025 results, Q4 business update. — PR
- Idorsia posts 2025 results; QUVIVIQ sales more than double. — PR
- BioCentury examines FDA’s single-trial default standard. — BioCentury
- SOTU healthcare remarks include no new policies, BioPharma Dive says. — BioPharma Dive
- FDA U-turn brings Immedica therapy to ultra-rare disease patients. — BioCentury
- Sarepta CEO Doug Ingram to retire, reports say. — STAT
- Alkermes CEO Pops to hand baton to COO Jackson, BioCentury says. — BioCentury
- Argo to present positive Phase 2 interim BW-20805 data in HAE. — PR
- Catalyst posts record Q4, full-year 2025 results; guides 2026. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Asahi Kasei to buy German biotech Aicuris for $920M. — Endpoints
- Scantox acquires DuplexSeq genomics safety business from TwinStrand. — PR
VC / Private Financings
-
Slate Medicines: $130M Series A — co-led by RA Capital, Forbion, and Foresite Capital. —
BioXconomy
IPOs / Follow-Ons
-
Larimar Therapeutics prices upsized $100M underwritten public offering (20M shares at $5.00 + greenshoe). —
PR
-
Bicara Therapeutics prices ~$150M public offering (shares + pre-funded warrants). —
PR
|
